Deal Watch: Lilly/Qiagen Tie-Up Leads Spate Of Cancer Diagnostic Partnerships
Bayer looks to augment Xofigo and its prostate cancer portfolio through development and commercialization pact with Orion around Phase III-ready asset once partnered with Endo. Meanwhile, Shire and arGEN-X expand a collaboration in which the latter’s antibody-discovery technologies are being used to discover potential candidates against targets chosen by Shire.
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.